Validation of a cell cycle progression score for 5-year mortality risk in patients with stage I non-small cell lung cancer.

7522 Background: The aim of this study was to validate a molecular expression signature [cell cycle progression (CCP) score] and a Prognostic Score [(PS) combination of CCP and pathological stage (IA or IB)] that identify stage I non-small cell lung cancer patients with a higher risk of cancer-related death after surgical resection. Methods: Formalin-fixed paraffin-embedded surgical tumor samples from 1200 patients diagnosed with stage I adenocarcinoma who underwent definitive surgical treatment without adjuvant chemotherapy were analyzed for 31 proliferation genes by quantitative RT-PCR. The prognostic discrimination of the CCP score and the PS were assessed by Cox proportional hazards regression using 5-year lung cancer death as primary outcome. Results: In a multivariate model the CCP score was a significant prognostic marker of 5-year lung cancer mortality [hazard ratio (HR) = 1.54 per interquartile range (95% confidence interval = 1.10–2.15; p = 0.0110)]. Other significant variables included age, tum...